scispace - formally typeset
Open AccessJournal ArticleDOI

Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain.

Reads0
Chats0
TLDR
The retention of a low level of residual reactogenicity in the A/Scotland/74 ca recombinant suggests that acquisition of the ca and temperature-sensitive phenotypes by a ca recombination virus may not always bring about a satisfactory level of attenuation for individuals lacking hemagglutinin immunity.
Abstract
Influenza A/Scotland/74 (H3N2) and A/Victoria/75 (H3N2) cold-adapted (ca) recombinant viruses, prepared by mating the A/Ann Arbor/6/60 (H2N2) ca donor virus and influenza A wild-type virus, were evaluated in adult seronegative volunteers (serum hemagglutination-inhibiting antibody titer, ≤1:8) for level of attenuation, antigenicity, and genetic stability of the temperature-sensitive and ca phenotypes. At 107.0 to 107.5 50% tissue culture infective doses the A/Scotland/74 and A/Victoria/75 ca recombinant viruses were clearly attenuated and antigenic. However, one of eight vaccinees infected with 107.5 50% tissue culture infective doses of the A/Scotland/74 ca recombinant had a febrile reaction (39°C). At a 10-fold higher dose (108.5 50% tissue culture infective doses), 4 of 12 A/Scotland/74 vaccinees had a febrile and/or systemic reaction. Febrile reactions were not observed in volunteers who received the A/Victoria/75 ca recombinant virus, whereas 3 of the 12 vaccinees had mild upper respiratory tract symptoms, in one instance associated with mild systemic manifestations. Significantly, the serum hemagglutination- and neuraminidase-inhibiting antibody responses were comparable to those induced by wild-type virus. Both ca recombinant viruses were shed in low titer for a short period of time. Each isolate retained the temperature-sensitive phenotype. However, there was evidence of genetic instability of the ca marker in that 7 of 24 isolates exhibited some loss of the ca property, and one isolate completely lost the capacity to produce plaques at 25°C. The retention of a low level of residual reactogenicity in the A/Scotland/74 ca recombinant suggests that acquisition of the ca and temperature-sensitive phenotypes by a ca recombinant virus may not always bring about a satisfactory level of attenuation for individuals lacking hemagglutinin immunity.

read more

Citations
More filters
Journal ArticleDOI

Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies

TL;DR: Prior expert opinion on the duration of viral shedding or the frequency of asymptomatic influenza infection is confirmed, prior knowledge on the dynamics of viral shed and symptoms is extended, and original results on the frequencyof respiratory symptoms or fever are provided.
Journal ArticleDOI

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.

TL;DR: Protective immunity to influenza A viruses is mediated primarily by serum IgG and mucosal IgA antibodies directed against the HA and NA, making it necessary that these two antigens are derived from the newly emerged antigenic variant virus.
Journal ArticleDOI

Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2).

TL;DR: In this article, RNA segments encoding the PB2, P131, PA, NP, M1, M2, NS1, and NS2 proteins of the influenza A/Ann Arbor/6/60 (H2N2) wild-type (wt) virus and its cold-adapted (ca) derivative that has been used for preparing investigational live attenuated vaccines were obtained.
Journal ArticleDOI

N6-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I.

TL;DR: This study reports a novel function for the N6-methyladenosine RNA modification in allowing RIG-I to discriminate self from non-self RNA and shows that human metapneumovirus induces this modification of its RNA to evade recognition in vivo.
Journal ArticleDOI

Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus.

TL;DR: The failure of the vaccine virus to infect some volunteers was correlated with the presence of pre-inoculation nasal wash immunoglobulin A hemagglutinin antibody, indicating that the vaccine retains some mild reactogenicity at a high dosage.
References
More filters
Journal Article

Influenzavirus neuraminidase and neuraminidase-inhibition test procedures.

TL;DR: The neuraminidase-inhibition test, as performed in the two WHO international reference centres for influenza, is described and its use in other laboratories-particularly those collaborating in the WHO programme-is recommended.
Journal ArticleDOI

Association of Serum Anti-Neuraminidase Antibody with Resistance to Influenza in Man

TL;DR: The role of serum anti-neuraminidase antibody in resistance to influenzal illness was investigated by administration of wild-type influenza A/Hong Kong/1968 (H3N2) virus to volunteers who had shown resistance to Influenza A.
Journal ArticleDOI

Adaptation and Growth Characteristics of Influenza Virus at 25° C

TL;DR: This work has shown that a relationship has been observed between virulence and the ability to grow at lower temperatures, and this has been used in the selection of attenuated variants.
Journal Article

Biologic and Immunologic Characteristics of Cold-Adapted Influenza Virus

Maassab Hf
TL;DR: Ferrets responded as did mice to infection with the cold variants; the animals showed no evidence of disease and developed good HI antibody response and ferrets that possessed circulating antibody showed a heightened antibody response after they were reinoculated intranasally with cold variant virus.
Journal ArticleDOI

Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man.

TL;DR: The use of a ts lesion that imposes a defined and desirable degree of attenuation upon influenza A virus and the transfer of this lesion to new antigenic variants of the virus offer some hope for the rapid development of a live vaccine for containment of pandemic disease.
Related Papers (5)